Skip to main content

Table 6 Univariate analysis of risk factors affecting clinical efficacy

From: Therapeutic effect of percutaneous kyphoplasty combined with anti-osteoporosis drug on postmenopausal women with osteoporotic vertebral compression fracture and analysis of postoperative bone cement leakage risk factors: a retrospective cohort study

Factor

Excellent efficacy group (n = 50)

General efficacy group (n = 62)

t2/Z

P

Age (years)

51.5 ± 3.1

51.1 ± 3.4

0.629

0.531

BMI (kg/m2)

23.01 ± 1.62

23.22 ± 1.92

0.618

0.538

Marital status

  

0.615

0.735

 Married

40 (80.00)

53 (85.48)

  

 Unmarried

3 (6.00)

3 (4.84)

  

 Divorced

7 (14.00)

6 (9.68)

  

Past medical history

    

 Hypertension

15 (30.00)

21 (33.87)

0.190

0.436

 Diabetes

10 (20.00)

22 (35.48)

3.252

0.071

 Hyperlipidemia

12 (24.00)

18 (29.03)

0.357

0.550

 Coronary heart disease

5 (10.00)

7 (11.29)

0.048

0.826

Place of residence

  

0.047

0.828

 City

42 (84.00)

53 (85.48)

  

 Rural area

8 (16.00)

9 (14.52)

  

Degree of education

  

0.155

0.734

 ≥ Senior high school

34 (68.00)

44 (70.97)

  

 < Senior high school

16 (32.00)

18 (29.03)

  

Causes

  

0.303

0.860

 Falling down

35 (70.00)

46 (74.19)

  

 Sprain

10 (20.00)

10 (16.13)

  

 Other

5 (10.00)

6 (9.68)

  

Site of injury vertebrae

  

−1.142

0.254

 T7

4 (6.56)

6 (7.23)

  

 T8

0 (0.00)

2 (2.41)

  

 T9

2 (3.28)

3 (3.61)

  

 T10

4 (6.56)

5 (6.02)

  

 T11

4 (6.56)

7 (8.43)

  

 T12

11 (18.03)

20 (24.10)

  

 L1

12 (19.67)

14 (16.87)

  

 L2

8 (13.11)

10 (12.05)

  

 L3

8 (13.11)

7 (8.43)

  

 L4

6 (9.84)

6 (7.23)

  

 L5

2 (3.28)

3 (3.61)

  

Use of zoledronic acid

  

3.949

0.047

 Used

32 (64.00)

28 (45.16)

  

 Unused

18 (36.00)

34 (54.84)

  

Fracture acuteness

    

 Acute

30 (60.00)

36 (58.06)

  

 Subacute

20 (40.00)

26 (41.94)

  

Peripheral vertebrae wall damage

  

2.637

0.104

 Damaged

8 (16.00)

18 (29.03)

  

 Undamaged

42 (84.00)

44 (70.97)

  

Bone cement dosage (mL)

5.08 ± 1.43

5.19 ± 1.01

0.479

0.633

TNF-α (pg/mL)

5.86 ± 1.81

6.08 ± 2.06

0.595

0.553

IL-6 (pg/mL)

11.03 ± 3.14

11.21 ± 3.40

0.289

0.773

BMD (g/cm2)

0.95 ± 0.21

0.92 ± 0.14

0.908

0.366

PINP (μg/L)

55.93 ± 5.82

55.18 ± 5.51

0.701

0.485

BGP (μg/L)

4.16 ± 0.73

4.13 ± 0.84

0.200

0.842

Vertebral height ratios of injured vertebrae (%)

75.02 ± 10.63

69.29 ± 9.19

6.822

< 0.001

Cobb angle (°)

15.98 ± 2.15

17.55 ± 3.54

2.757

0.007

VAS score

3.04 ± 1.65

2.80 ± 1.25

0.879

0.381

ODI score

26.52 ± 10.15

38.55 ± 7.30

7.322

< 0.001

  1. BMI body mass index, TNF-α tumor necrosis factor-α, IL-6 Interleukin-6, BMD bone mineral density, PINP procollagen type I N-terminal propeptide, BGP bone gla protein, VAS visual analogue scale/score, ODI Oswestry disability index